Global Healthcare Investment Report: 153 Financing Deals and $3.96B Disclosed in December 2024

According to incomplete statistics from the Arterial Orange Industry Think Tank, in December 2024, there were a total of 153 financing events in the global healthcare sector (excluding IPOs, private placements, etc.), with disclosed financing amounting to approximately $3.962 billion (about 28.649 billion RMB). Among these, 66 financing events occurred in the Chinese market, with disclosed financing totaling about $558 million; overseas markets saw 87 financing events, with disclosed financing reaching approximately $3.104 billion.。

Compared with November 2024, the total amount of global healthcare industry financing in December 2024 increased slightly by about 37.27% month-over-month in terms of transaction value, number of financing events, and focus on emerging fields, while the number of events decreased by approximately 8.38% month-over-month.

In terms of large financing events, there were 12 events exceeding 100 million US dollars this month, with a cumulative financing amount reaching 1.729 billion US dollars. Among these, 11 occurred in overseas regions and 1 took place in China. The 12 companies are: SandboxAQ, an artificial intelligence and computing solutions developer; Oura Health, a sleep health platform operator; Redesign Health, a healthcare technology developer; Nuvig Therapeutics, a developer of transformative therapies for chronic inflammation and autoimmune diseases; Ottimo Pharma, an innovative cancer therapy developer; Angitia, a developer of innovative drugs for musculoskeletal and joint diseases; Maze Therapeutics, a developer of treatments for genetic disorders; Capstan Medical, a minimally invasive technology developer; Cleerly, an AI-powered digital care platform developer; Precision Neuroscience, a brain-computer interface developer; Remodel Health, a provider of health benefits solutions; and SiteOne Therapeutics, a pain medication developer.

In terms of global medical and health industry sub-sector financing, compared to medical services and pharmaceutical commerce, biopharmaceuticals, medical devices and consumables, and digital health dominated in December in terms of total financing amount and number of events: the number of financing events for biopharmaceuticals and medical devices and consumables were similar this month, with their combined total accounting for 71.24% of the entire field; the total financing amount for biopharmaceuticals accounted for the highest proportion of the total financing amount across all fields, reaching 46.39%; the total financing amount for digital health in December increased significantly compared to November, with a month-on-month increase of approximately 123.1%.

Notably, SandboxAQ, an artificial intelligence technology company, has completed a $300 million financing round, securing the top spot in this month's funding. SandboxAQ is dedicated to providing cutting-edge AI and advanced computing solutions. Its Large Quantitative Models (LQM) address critical challenges in drug discovery, new materials for the automotive and aerospace industries, and investment asset management. SandboxAQ’s AI sensing applications are revolutionizing healthcare and navigation, while its groundbreaking cryptographic management platform protects organizations from current and future cyber threats.

On December 19, 2024, ŌURA, the world's leading smart ring manufacturer, announced that it had secured $200 million in Series D funding, raising its valuation to $5.2 billion. The investment, which included participation from Fidelity Management & Research Company and Dexcom, will be used to enhance ŌURA’s product offerings, invest in R&D, expand globally, and pursue strategic acquisitions.

On December 19, 2024, Anglo-American biotechnology company Ottimo Pharma completed a large early-stage biotech financing round, raising $140 million for its PD-1 and VEGF-targeted drug jankistomig, intended for cancer treatment. The round was co-led by Orbimed, Avoro Capital Advisors, Avoro Ventures, and Samsara BioCapital. Jankistomig is a "first-in-class bifunctional antibody," distinct from bispecific antibodies, designed to block the PD-1 and VEGF pathways while minimizing VEGF-related adverse effects.

Health Benefits Solutions Provider Remodel Health Announces Over $100 Million in Significant Growth Funding to Expand ICHRA Business

On December 19, 2024, Remodel Health, a provider of Individual Coverage Health Reimbursement Arrangements (ICHRAs), announced it has secured over $100 million in significant growth funding led by OakHC/FT and Hercules Capital. Remodel Health's technology platform streamlines the creation and management of ICHRA plans while offering employee onboarding, HRIS integration, and access to ancillary products. The ICHRA market is rapidly expanding, providing flexibility, cost savings, tax advantages, and access to ACA exchanges. Remodel Health plans to use this funding round to support the continued expansion and innovation of its ICHRA market.

SandboxAQ, a company specializing in Large Quantitative Models (LQMs) and artificial intelligence solutions, has raised over $300 million from various renowned investors, valuing the company at $5.3 billion. CEO Jack D. Hidary emphasized the importance of LQMs in addressing scientific and commercial challenges across major industries, viewing this financing as a means to make a significant impact. The company also recognizes the complementarity of LLMs and LQMs in B2B application fields.

On December 18, 2024, painkiller developer SiteOne Therapeutics, Inc. announced the completion of a $100 million Series C financing round. The round was led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and BSQUAREDCapital.With the participation of existing investors, SiteOne's development of a selective small molecule ion channel modulator portfolio will be supported, advancing through human clinical proof-of-concept to treat sensory hypersensitivity disorders.

Brain-Computer Interface Developer Precision Neuroscience Secures $102 Million in Series C Funding to Advance AI Brain Implants

On December 17, 2024, brain-computer interface developer Precision Neuroscience secured $102 million in Series C funding, led by General.Equity Holdings led the investment round, with participating companies including B Capital, Stanley F. Druckenmiller's investment firm Duquesne Family Office, and Steadview Capital. Precision will use the new funding to expand its team, advance its clinical research efforts, and enhance future versions of its AI-driven brain implant, which is designed to enable severely paralyzed users to operate digital devices such as computers and smartphones using only their thoughts.

Healthcare Technology Developer Redesign Health Secures $175 Million in Funding to Launch New Medtech Companies

On December 12, 2024, healthcare technology developer Redesign Health secured $175 million in funding, with participation from Declaration Partners, Euclidean Capital, and True North Advisors. The company will use the funds to establish companies addressing healthcare workforce shortages, accelerate value-based and longitudinal care, enhance healthcare interoperability, prepare for an aging population, improve health equity, expand care locations, broaden insured populations, and drive the personalization and consumerization of healthcare.

Angitia Completes $120 Million Series C Financing Led by Bain Capital

On December 11, 2024, Angitia announced the completion of its $120 million Series C financing. This round was led by Bain Capital, with new investors Janus Henderson joining, and existing shareholders OrbiMed, Sanchen Health Investment, Yonghua Capital, Yonhua Investment, Legend Capital, and Richelieu Investment participating. The proceeds from the Series C financing will support Angitia's robust pipeline of novel differentiated therapies for severe musculoskeletal disorders.

Minimally Invasive Technology Developer Capstan Medical Raises $110 Million in Series C Funding to Advance Minimally Invasive Heart Valve Therapies

On December 11, 2024, Capstan Medical, a developer of minimally invasive technologies, raised $110 million in Series C funding led by Eclipse, with participation from existing investors Yu Galaxy and Intuitive Ventures, as well as new investment from Gideon Strategic Partners. This new funding will enable the company to: Accelerate Clinical Trials: Conduct pivotal clinical trials to demonstrate the safety and efficacy of its technology. Expand R&D: Further refine and enhance its minimally invasive solutions. Scale Operations: Prepare for commercialization and broaden its reach, bringing its technology to more patients.

Nuvig Therapeutics, a Novel Immunomodulatory Therapy, Secures $161 Million in Series B Funding and Advances to Phase II Development of Second-Generation Novel Immunomodulators

Nuvig Therapeutics, a biotechnology company developing immunomodulatory therapies for inflammatory autoimmune diseases, announced the closure of a $161 million Series B financing round led by Sanofi Ventures, Blue Owl Healthcare Opportunities, and Norwest Venture Partners. The funding will support the clinical advancement of NVG-2089, a novel immunomodulator designed to reduce autoimmune dysregulation without immunosuppression. New and existing investors, including B Capital, Leaps by Bayer, and Novo Holdings A/S, participated in the round. Nuvig aims to bring potentially transformative medicines to patients.

Healthcare Service Provider Cleerly Secures $106 Million Series C Extension Funding to Further Expand Commercial Growth and Clinical Evidence Generation

On December 4, 2024, healthcare services provider Cleerly secured a $106 million Series C extension round. The round was led by global software investor Insight Partners, with participation from Battery Ventures and existing investors. With this new funding, Cleerly will continue to expand its commercial growth and clinical evidence generation, helping healthcare professionals improve patient outcomes across the entire coronary care pathway.

Genetic Disease Treatment Drug Developer Maze Therapeutics Secures $115 Million in Series D Funding

On December 3, 2024, Maze Therapeutics, a developer of treatments for genetic diseases, announced the completion of a $115 million Series D financing round, which included the conversion of previously issued convertible notes purchased by existing investors. The Series D financing was co-led by Frazier Life Sciences and Deep Track Capital. Janus Henderson Investors and Logos Capital also participated in the investment. Existing investors include Third Rock Ventures, ARCH Venture Partners, Matrix Capital Management, GV, General Catalyst, Andreessen Horowitz (a16z), Foresite Capital, Woodline Partners LP, Casdin Capital, and Piper.Heartland Healthcare Capital, Moore Strategic Ventures, and other existing leading healthcare investors. Maze Therapeutics is a clinical-stage biopharmaceutical company leveraging the power of human genetics to develop novel small-molecule precision medicines for patients with kidney, cardiovascular, and metabolic diseases.。

The above is the monthly report summary, more monthly report content is as follows:

Global Biomedical Investment and Financing in December 2024

Global Medical Device Investment and Financing in December 2024

Global Digital Health Investment and Financing in December 2024

Global Healthcare Investment and Financing in December 2024

Global Pharmaceutical Business Investment and Financing in December 2024

Welcome ImmediatelyScan the QR code to add the assistantGetCompleteMonthly ReportAndApply for a Free Trial Database, please inquire proactively if added: